AIMS: To compare two different multiparameter histopathological scoring indices and determine their prognostic value in patients presenting with adrenocortical carcinoma (ACC). METHODS AND RESULTS: Seventy-nine adrenal cortical tumours were divided into adenomas (n = 17), non-metastatic carcinomas (n = 24) and carcinomas with metastatic disease and/or local recurrence during follow-up (n = 19) or at time of presentation (n = 19). All cases were scored according to the Weiss revisited index (WRI) and the Van Slooten index (VSI). Both scoring indices yielded a significantly different score (P < 0.005) between adenomas and carcinomas. Non-metastasized carcinomas had a lower score with both indices compared with carcinomas with metastases at the time of presentation (VSI, P = 0.017; WRI, P = 0.019). The VSI also distinguished ACC that had metastasized at any time from those that had not (P = 0.015). Cancer-specific survival in patients with metastasized ACC correlated with the scores for both indices (VSI, P = 0.0078; WRI, P = 0.0025). Time from diagnosis of ACC to development of metastatic disease was correlated with the WRI (P = 0.036, r = -0.350). CONCLUSIONS: The VSI and the WRI have equal validity in the correct categorization of ACC and adenomas. Furthermore, both indices show a correlation with survival for metastasizing ACC.
AIMS: To compare two different multiparameter histopathological scoring indices and determine their prognostic value in patients presenting with adrenocortical carcinoma (ACC). METHODS AND RESULTS: Seventy-nine adrenal cortical tumours were divided into adenomas (n = 17), non-metastatic carcinomas (n = 24) and carcinomas with metastatic disease and/or local recurrence during follow-up (n = 19) or at time of presentation (n = 19). All cases were scored according to the Weiss revisited index (WRI) and the Van Slooten index (VSI). Both scoring indices yielded a significantly different score (P < 0.005) between adenomas and carcinomas. Non-metastasized carcinomas had a lower score with both indices compared with carcinomas with metastases at the time of presentation (VSI, P = 0.017; WRI, P = 0.019). The VSI also distinguished ACC that had metastasized at any time from those that had not (P = 0.015). Cancer-specific survival in patients with metastasized ACC correlated with the scores for both indices (VSI, P = 0.0078; WRI, P = 0.0025). Time from diagnosis of ACC to development of metastatic disease was correlated with the WRI (P = 0.036, r = -0.350). CONCLUSIONS: The VSI and the WRI have equal validity in the correct categorization of ACC and adenomas. Furthermore, both indices show a correlation with survival for metastasizing ACC.
Authors: A Stigliano; I Chiodini; R Giordano; A Faggiano; L Canu; S Della Casa; P Loli; M Luconi; F Mantero; M Terzolo Journal: J Endocrinol Invest Date: 2015-07-14 Impact factor: 4.256
Authors: Johannes Hofland; Jacobie Steenbergen; Jacoba M Voorsluijs; Michael M P J Verbiest; Ronald R de Krijger; Leo J Hofland; Wouter W de Herder; Andre G Uitterlinden; Richard A Feelders; Frank H de Jong Journal: PLoS One Date: 2014-08-11 Impact factor: 3.240
Authors: Mark J McCabe; Mark Pinese; Chia-Ling Chan; Nisa Sheriff; Tanya J Thompson; John Grady; Marie Wong; Marie-Emilie A Gauthier; Clare Puttick; Velimir Gayevskiy; Elektra Hajdu; Stephen Q Wong; Wade Barrett; Peter Earls; Robyn Lukeis; Yuen Y Cheng; Ruby C Y Lin; David M Thomas; D Neil Watkins; Marcel E Dinger; Ann I McCormack; Mark J Cowley Journal: Cold Spring Harb Mol Case Stud Date: 2019-04-01
Authors: J Waldmann; G Feldmann; E P Slater; P Langer; M Buchholz; A Ramaswamy; W Saeger; M Rothmund; V Fendrich Journal: Br J Cancer Date: 2008-11-18 Impact factor: 7.640